{"type":"trials","record":{"id":42290,"source_id":"clinicaltrials-gov","external_id":"NCT04907409","title":"Home OCT Fluid Visualization Agreement Study","brief_summary":"This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with scheduled in-office examinations at Week 1, Week 5 and Interim Visits, when applicable, with additional in-office Cirrus volume scans acquired at these office visits. The self-imaging data on the NVHO will be automatically uploaded to the Notal Health Cloud and from there the reconstructed volume scans will sent to the study database.","overall_status":"Unknown","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Notal Vision Inc.","enrollment":120,"countries":["United States"],"start_date":"2021-06-17","completion_date":"2022-08-30","last_update_date":"2022-03-09","source_url":"https://clinicaltrials.gov/study/NCT04907409","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"55 Years","comparator":null,"organization":"Notal Vision Inc.","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Positive percent agreement — 1 month following reading center grading completion","Negative percent agreement — 1 month following reading center grading completion","Percentage of subjects who successfully completed the setup of the NVHO device — 5-10 minutes","Percentage of subjects who Successful completed NVHO self-imaging — 2-3 minutes","Percentage of all sessions that were transmission successfully — 10-15 minutes","Percentage of sessions containing self-imaging that were transmitted successfully — 10-15 minutes"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration"],"relevance_confidence":62,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04907409","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-06-17 to 2022-08-30","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.946Z","intervention":[],"participants":120,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Positive percent agreement — 1 month following reading center grading completion","Negative percent agreement — 1 month following reading center grading completion","Percentage of subjects who successfully completed the setup of the NVHO device — 5-10 minutes","Percentage of subjects who Successful completed NVHO self-imaging — 2-3 minutes","Percentage of all sessions that were transmission successfully — 10-15 minutes","Percentage of sessions containing self-imaging that were transmitted successfully — 10-15 minutes"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: aging.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","abstract context","study type"],"relevance_score":62,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42290","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}